购物车
- 全部删除
- 您的购物车当前为空
NUCC-390 是新型的选择性小分子 CXCR4 receptor 受体激动剂。NUCC-390 可以诱导 CXCR4 受体的内化,作用方式与 AMD3100相反。NUCC-390 在动物模型中,有助于神经退行性变后神经功能恢复。
NUCC-390 是新型的选择性小分子 CXCR4 receptor 受体激动剂。NUCC-390 可以诱导 CXCR4 受体的内化,作用方式与 AMD3100相反。NUCC-390 在动物模型中,有助于神经退行性变后神经功能恢复。
规格 | 价格 | 库存 | 数量 |
---|---|---|---|
1 mg | ¥ 1,480 | 现货 | |
5 mg | ¥ 3,110 | 现货 | |
10 mg | ¥ 4,570 | 现货 | |
25 mg | ¥ 7,260 | 现货 | |
50 mg | ¥ 9,790 | 现货 | |
100 mg | ¥ 13,200 | 现货 | |
500 mg | ¥ 26,300 | 现货 | |
1 mL x 10 mM (in DMSO) | ¥ 3,550 | 现货 |
产品描述 | NUCC-390, a novel small-molecule CXCR4 receptor agonist, selectively induces CXCR4 receptor internalization while acting antagonistically to AMD3100. This compound facilitates nerve functional recovery following neurodegeneration in vivo. |
体外活性 | NUCC-390 (10 μM) produces strong (Ca)i response, but this effect can be blocked by the known potent and selective CXCR4 antagonist AMD3100. NUCC-390 (10 μM; pre-treatment 30 mins) leads to increased levels of pERK, it has the capability of stimulating signaling activity downstream of CXCR4 receptors. NUCC-390 (10 μM; 2 hours) can induce CXCR4 receptor internalization, and non-treated cells exhibit some diffuse expression of CXCR4-YFP throughout the cytosol and clear expression in the cell membrane in HEK cells[1]. NUCC-390 (0-1.25 μM; 24 hours) boosts axonal growth in cultured cerebellar granule neurons (CGNs) via CXCR4[2]. |
体内活性 | NUCC-390 (hind limb injection; 3.2 mg/kg; twice daily; 3 days) contributes to the functional and anatomical recovery of the neuromuscular junction (NMJ) following an acute nerve terminal damage by α-LTx in CD-1 mice[2]. |
分子量 | 395.54 |
分子式 | C23H33N5O |
CAS No. | 1060524-97-1 |
存储 | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. | |||||||||||||||||||||||||||||||||||
溶解度信息 | DMSO: 60 mg/mL (151.69 mM) | |||||||||||||||||||||||||||||||||||
溶液配制表 | ||||||||||||||||||||||||||||||||||||
DMSO
|
版权所有©2015-2024 TargetMol Chemicals Inc.保留所有权利.